These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 35896235

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibitory Effect of Pyra-Metho-Carnil on Cancer Spheroid Growth Through Decrease in Glycolysis-associated Molecules.
    Yoshida K, Nishi K, Ishikura S, Matsumoto T, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2023 Aug; 43(8):3717-3726. PubMed ID: 37500165
    [Abstract] [Full Text] [Related]

  • 3. Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.
    Hashimoto S, Nagai M, Nishi K, Ishikura S, Nakabayashi K, Yazaki R, Ohshima T, Suenaga M, Shirasawa S, Tsunoda T.
    Anticancer Res; 2021 Aug; 41(8):4061-4070. PubMed ID: 34281875
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS.
    Nishi K, Luo H, Ishikura S, Doi K, Iwaihara Y, Wills L, Baillie GS, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2017 Jul; 37(7):3833-3839. PubMed ID: 28668883
    [Abstract] [Full Text] [Related]

  • 7. Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules.
    Tsunoda T, Ishikura S, Doi K, Iwaihara Y, Hidesima H, Luo H, Hirose Y, Shirasawa S.
    Anticancer Res; 2015 Aug; 35(8):4453-9. PubMed ID: 26168486
    [Abstract] [Full Text] [Related]

  • 8. MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant KRAS.
    Nishi K, Tsunoda T, Uchida Y, Sueta T, Sawatsubashi M, Yamano T, Hashiguchi Y, Swain A, Shirasawa S, Sakata T.
    Anticancer Res; 2020 Aug; 40(8):4687-4694. PubMed ID: 32727793
    [Abstract] [Full Text] [Related]

  • 9. Mutant KRAS Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion.
    Nishi K, Ishikura S, Umebayashi M, Morisaki T, Inozume T, Kinugasa T, Aoki M, Nimura S, Swain A, Yoshida Y, Hasegawa S, Nabeshima K, Sakata T, Shirasawa S, Tsunoda T.
    Anticancer Res; 2020 Aug; 40(8):4663-4674. PubMed ID: 32727790
    [Abstract] [Full Text] [Related]

  • 10. Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells.
    Nishikawa G, Kawada K, Hanada K, Maekawa H, Itatani Y, Miyoshi H, Taketo MM, Obama K.
    Cells; 2022 Oct 18; 11(20):. PubMed ID: 36291140
    [Abstract] [Full Text] [Related]

  • 11. A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation.
    Okamoto H, Matsukawa T, Doi S, Tsunoda T, Sawata Y, Naemura M, Ohnuki K, Shirasawa S, Kotake Y.
    Mol Cell Biochem; 2018 May 18; 442(1-2):39-45. PubMed ID: 28936721
    [Abstract] [Full Text] [Related]

  • 12. The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway.
    Ogishima J, Taguchi A, Kawata A, Kawana K, Yoshida M, Yoshimatsu Y, Sato M, Nakamura H, Kawata Y, Nishijima A, Fujimoto A, Tomio K, Adachi K, Nagamatsu T, Oda K, Kiyono T, Osuga Y, Fujii T.
    BMC Cancer; 2018 Dec 03; 18(1):1201. PubMed ID: 30509235
    [Abstract] [Full Text] [Related]

  • 13. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRASG13D mutation.
    Charitou T, Srihari S, Lynn MA, Jarboui MA, Fasterius E, Moldovan M, Shirasawa S, Tsunoda T, Ueffing M, Xie J, Xin J, Wang X, Proud CG, Boldt K, Al-Khalili Szigyarto C, Kolch W, Lynn DJ.
    Br J Cancer; 2019 Jul 03; 121(1):37-50. PubMed ID: 31133691
    [Abstract] [Full Text] [Related]

  • 14. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA, Spolverato G, Kim Y, Karagkounis G, Choti MA, Pawlik TM.
    Ann Surg Oncol; 2015 Dec 03; 22(13):4158-65. PubMed ID: 26077912
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer.
    Tambe Y, Terado T, Kim CJ, Mukaisho KI, Yoshida S, Sugihara H, Tanaka H, Chida J, Kido H, Yamaji K, Yamamoto T, Nakano H, Omura S, Inoue H.
    Mol Carcinog; 2019 Oct 03; 58(10):1726-1737. PubMed ID: 31106493
    [Abstract] [Full Text] [Related]

  • 16. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC, Qian Y, Li X, Xu J, Kang W, Tong JH, To KF, Jin Y, Li W, Chen H, Go MY, Wu JL, Cheng KW, Ng SS, Sung JJ, Cai Z, Yu J.
    Gastroenterology; 2016 Nov 03; 151(5):945-960.e6. PubMed ID: 27451147
    [Abstract] [Full Text] [Related]

  • 17. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.
    Maitra R, Seetharam R, Tesfa L, Augustine TA, Klampfer L, Coffey MC, Mariadason JM, Goel S.
    Oncotarget; 2014 May 15; 5(9):2807-19. PubMed ID: 24798549
    [Abstract] [Full Text] [Related]

  • 18. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 19. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 20. Synthesis of New Congeners of 1-methyl-3-aminoisoquinolines, Evaluation of Their Cytotoxic Activity, In Silico and In Vitro Study of Their Molecular Targets as PDE4B.
    Lapa GB, Tsunoda T, Shirasawa S, Baryshnikova MA, Evseev GG, Afanasyeva DA, Chigorina EA.
    Chem Biol Drug Des; 2016 Apr 14; 87(4):575-82. PubMed ID: 26613238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.